Skip to content
zameds

Tenofovir alafenamide (Descovy, Vemlidy, Biktarvy)

Tenofovir alafenamide

Gilead Sciences South Africa (Pty) Ltd

Registration

Applicant
Gilead Sciences South Africa (Pty) Ltd
Certificate holder
Gilead Sciences South Africa (Pty) Ltd
Registrations
4

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Descovy 200/10

EACH TABLET CONTAINS EMTRICITABINE 200,0 mg TENOFOVIR ALAFENAMIDE FUMARATE EQUIVALENT TO TENOFOVIR ALAFENAMIDE 10,0 mg

200/10Film coated tablet51050651/20.2.8/0506Approved 3 November 2020RegisteredNot determinedPIPIL
Descovy 200/25

EACH TABLET CONTAINS EMTRICITABINE 200,0 mg TENOFOVIR ALAFENAMIDE FUMARATE EQUIVALENT TO TENOFOVIR ALAFENAMIDE 25,0 mg

200/25Film coated tablet51050751/20.2.8/507Approved 3 November 2020RegisteredNot determinedPIPIL
Vemlidy

EACH TABLET CONTAINS: TENOFOVIR ALAFENAMIDE FUMARATE EQUIVALENT TO TENOFOVIR ALAFENAMIDE 25,0 mg

25mgFilm coated tablet52027352/20.2.8/0273Approved 19 June 2025RegisteredNot determinedPIPIL
Biktarvy 30 mg/120 mg/15 MG film-coated tablets

BICTEGRAVIR SODIUM EQUIVALENT TO BICTEGRAVIR 30,0 mg EMTRICITABINE 120,0 mg TENOFOVIR ALAFENAMIDE FUMARATE EQUIVALENT TO TENOFOVIR ALAFENAMIDE 15,0 mg

30 mg/120 mg/15 mgFilm-coated tablets61029561/20.2.8/0295RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Bictegravir

    Consolidated Schedules 06 July 2026, line 5495

  • S4: Dolutegravir

    Consolidated Schedules 06 July 2026, line 6100

  • S4: Emtricitabine

    Consolidated Schedules 06 July 2026, line 6178

  • S4: Rilpivirine

    Consolidated Schedules 06 July 2026, line 7808

  • S4: Tenofovir

    Consolidated Schedules 06 July 2026, line 8130

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C21H29N6O5P476.50 g/mol

Propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate

Drag to rotate. Structure from PubChem CID 9574768.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles